REPORT: Amgen sweetens offer for Onyx, bid falls short of share price
This article was originally published in Scrip
Amgen increased its bid for Onyx Pharmaceuticals to $130 a share, a move that would value the takeover at about $10.9 billion, Bloomberg News reported.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.